Cantor Fitzgerald Reaffirms Their Buy Rating on Insys Therapeutics (INSY)
Cantor Fitzgerald analyst Brandon Folkes reiterated a Buy rating on Insys Therapeutics (INSY) yesterday and set a price target of $9. The company’s shares closed yesterday at $5.68.
“: Post 4Q18, we are reiterating our Overweight rating and a 12-month price target of $9 on INSY shares. We believe 2019 will be a pivotal and transformational year for Insys. The company has two potential filings with its spray platform this year, along with two significant data readouts from the company’s cannabinoids platform, and PWS later in the year. We believe 2019 could be the year in which investors are able to return to INSY stock and appreciate the value that could be unlocked from within the company’s spray and cannabinoids pipeline.”
According to TipRanks.com, Folkes is a 3-star analyst with an average return of 4.7% and a 42.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
Currently, the analyst consensus on Insys Therapeutics is a Moderate Buy with an average price target of $10.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.65 and a one-year low of $3.35. Currently, Insys Therapeutics has an average volume of 993.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
INSYS Therapeutics, Inc. is a c pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products.